» Articles » PMID: 8139611

Increased Levels of Lipid Hydroperoxides in the Parkinsonian Substantia Nigra: an HPLC and ESR Study

Overview
Journal Mov Disord
Date 1994 Jan 1
PMID 8139611
Citations 92
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies examining the involvement of oxidative stress in the substantia nigra in Parkinson's disease have measured terminal products of lipid peroxidation or the function of antioxidant defense systems. We report a more specific early marker of lipid peroxidation, lipid hydroperoxides, in a high-performance liquid chromatography (HPLC) and electron spin resonance (ESR) investigation. HPLC-chemiluminescent detection revealed two classes of lipid hydroperoxides in brain tissue extracts--free fatty acid hydroperoxides and cholesterol lipid hydroperoxides. Only cholesterol lipid hydroperoxides were consistently detected in all tissue extracts. Cholesterol lipid hydroperoxides had a 10-fold increase in the Parkinson's disease substantia nigra compared to control subjects. ESR detection of radical degradation products, including those of lipid hydroperoxides, in nigral homogenates incubated with the spin trap N-t-butyl-alpha-phenyl nitrone (PBN) showed a marked variation in ESR signal between tissues. Despite the increased levels of lipid hydroperoxides in parkinsonian substantia nigra, there was no overall difference in ESR signal intensity between nigral tissues from controls and from patients with Parkinson's disease. The increased levels of an early component of the peroxidation chain in substantia nigra in Parkinson's disease support the hypothesis of a continuous toxic process involving oxygen radical activity. However, using previously frozen tissue, ESR evidence for increased radical formation could not be demonstrated.

Citing Articles

6-Shogaol Abrogates Parkinson's Disease in Rotenone-Induced Rodents: Based on In Silico Study and Inhibiting TNF-α/NF-κB/IL-1β/MAO-B.

Rafeeq M, Al-Abbasi F, Afzal M, Moglad E, Al-Qahtani S, Alzrea S Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458989 PMC: 11510247. DOI: 10.3390/ph17101348.


Neuroprotective Roles of the Biliverdin Reductase-A/Bilirubin Axis in the Brain.

Paul B, Pieper A Biomolecules. 2024; 14(2).

PMID: 38397392 PMC: 10887292. DOI: 10.3390/biom14020155.


Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse model.

Fang T, Sun Y, Pearce A, Eleuteri S, Kemp M, Luckhurst C Nat Commun. 2023; 14(1):7295.

PMID: 37957154 PMC: 10643470. DOI: 10.1038/s41467-023-42876-1.


Carotenoids: Role in Neurodegenerative Diseases Remediation.

Gandla K, Babu A, Unnisa A, Sharma I, Singh L, Haque M Brain Sci. 2023; 13(3).

PMID: 36979267 PMC: 10046158. DOI: 10.3390/brainsci13030457.


Preliminary Effects of Osteopathic Manipulative Medicine on Reactive Oxygen Species in Parkinson's Disease: A Randomized Controlled Pilot Study.

Docherty J, Leheste J, Mancini J, Yao S Cureus. 2022; 14(11):e31504.

PMID: 36532904 PMC: 9750800. DOI: 10.7759/cureus.31504.